✨ Ask AkshayaAI anything about this stock — instant AI answers. Try the AI assistant →
AkshayaAIStocks › EXEL

EXEL — Exelixis Inc

AI Signal & Stock Analysis · Weak ↓

As of Aug 14 2026, 1:04 PM, AkshayaAI's signal for EXEL is Weak ↓; the stock is at $51.12 (+1.00% today); neutral (RSI 41); technical trend is down-trend; news sentiment is positive.

Data as of Aug 14 2026, 1:04 PM. Informational analytics only — not investment advice.

Key metrics

AI signal (Strength)Weak ↓
Price$51.12
Change today+1.00%
RSI (14)40.87
Relative volume0.37
Composite (RMTPGV) score🔒 members
Market cap$12.7B
Forward P/E12.76
52-week high-11.3% away
52-week low+51.4% above
Technical trendDown-trend (since 2024-01-26)
News sentimentPositive
SectorHealthcare-Biotech
Next earnings8/5/2026 4:30:00 PM

What's driving the signal

🔒 AkshayaAI factor scores — Momentum, Technical, Performance, Growth, Volatility and the composite RMTPGV score are members-only. Sign in free to see the full breakdown →
Ask a follow-up or get live data on EXEL → open the AI assistant

Frequently asked about EXEL

What is AkshayaAI's signal for EXEL today?

As of Aug 14 2026, 1:04 PM, AkshayaAI assigns EXEL (Exelixis Inc) a Weak signal. The composite (RMTPGV) score and full factor breakdown are available to signed-in members.

Is EXEL overbought or oversold right now?

EXEL's RSI is neutral (RSI 41). A reading above 70 is typically considered overbought and below 30 oversold.

Where is EXEL in its 52-week range?

EXEL is trading about 11% below its 52-week high and 51% above its 52-week low as of Aug 14 2026, 1:04 PM.

When is EXEL's next earnings date?

EXEL's next earnings date is 8/5/2026 4:30:00 PM.

What sector is EXEL in?

EXEL is classified under Healthcare-Biotech in AkshayaAI's taxonomy.

AkshayaAI provides AI-generated, informational stock analytics for US and India markets. This is not personalized investment advice. Figures are as of Aug 14 2026, 1:04 PM and may not reflect real-time prices. Always do your own research.

🤖

Ask AkshayaAI about EXEL

Instant, data-backed answers — free to try.